Acute-on-chronic liver failure (ACLF) in hospitalised patients with decompensated cirrhosis carries high short-term mortality, necessitating precise diagnostic and prognostic tools. The newly developed A-TANGO organ failure (OF) score aims to refine ACLF diagnosis and enhance its utility for treatment response evaluation and risk stratification, addressing limitations of existing criteria.1,2
- The Pivot The A-TANGO organ failure score provides updated, tailored criteria for ACLF diagnosis and prognostication, improving upon the widely used EASL-CLIF criteria.
- The Data The A-TANGO score was developed and validated in global cohorts to refine ACLF diagnosis and enhance utility for treatment response and risk stratification.1,2
- The Action Clinicians should consider the A-TANGO score for more precise ACLF diagnosis and prognostication, particularly in the context of evolving definitions of organ dysfunction and emerging therapies.
Acute-on-chronic liver failure (ACLF) is a severe condition characterised by multiorgan failure and high short-term mortality in hospitalised patients experiencing acute decompensation of cirrhosis.1,2 While the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) criteria have been widely adopted for both diagnosis and prognostication, ongoing advancements in understanding organ dysfunction and the emergence of new therapeutic approaches necessitate updated, more precise criteria.1,2 The objective of this research was to develop and validate the A-TANGO organ failure (OF) score, with the aim of refining ACLF diagnosis and improving its applicability for evaluating treatment response and stratifying patient risk.1,2
Development and Validation of the A-TANGO Score
The A-TANGO organ failure (OF) score was developed and validated through a comprehensive process involving global cohorts.1,2 The primary goal was to create a diagnostic and prognostic tool that offers enhanced accuracy for ACLF, particularly in light of evolving definitions of organ dysfunction and the availability of new therapies.1,2 The development process focused on tailoring criteria to improve diagnostic precision, facilitate the assessment of treatment efficacy, and enhance risk stratification capabilities within clinical trials and practice.1,2
The validation of the A-TANGO score involved assessing its performance against existing diagnostic criteria, specifically the EASL-CLIF criteria.1,2 The research aimed to demonstrate that the A-TANGO score could provide a more refined diagnosis of ACLF, leading to improved prognostication for hospitalised patients with acute decompensation of cirrhosis.1,2 The utility of the score extends to its potential for more accurate evaluation of patient response to interventions and for better categorising patients based on their risk of short-term mortality.1,2
In a related but distinct area, the European Association for the Study of the Liver (EASL) algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) has been adopted and validated in low-resource South Asian settings.3 This initiative highlights the broader effort within hepatology to improve diagnostic accuracy and accessibility for various liver conditions, including those that can progress to cirrhosis and potentially ACLF.3 While not directly part of the A-TANGO score development, the validation of noninvasive fibrosis algorithms underscores the importance of accurate and accessible diagnostic tools in managing advanced chronic liver disease globally.3
Limitations and Future Directions
The abstracts provided indicate that the A-TANGO score was developed and validated in global cohorts, suggesting a broad applicability.1,2 However, specific details regarding the size, diversity, and characteristics of these cohorts, as well as the precise methodology of the validation, are not detailed in the abstracts.1,2 Further investigation into the full papers would be necessary to understand the exact components of the A-TANGO score, its specific performance metrics (e.g., sensitivity, specificity, predictive values), and how it directly compares to the EASL-CLIF criteria in terms of clinical outcomes.1,2 The abstracts state the aim to improve diagnostic accuracy, treatment assessment, and applicability in clinical trials, but the extent to which these aims were met with quantifiable results remains to be fully elucidated.1,2 Future research will likely focus on prospective validation in diverse clinical settings and integration into clinical decision-making algorithms to assess its real-world impact on patient management and outcomes.
The introduction of the A-TANGO organ failure score represents a necessary evolution in the diagnosis and prognostication of acute-on-chronic liver failure. While the EASL-CLIF criteria have served their purpose, the landscape of liver disease management, particularly with emerging therapies, demands more granular and adaptable tools. Clinicians managing patients with decompensated cirrhosis should anticipate a shift in diagnostic paradigms, requiring familiarity with the A-TANGO score to accurately stratify risk and assess treatment response. This is not merely an academic exercise; precise diagnosis directly impacts resource allocation and the intensity of care, potentially influencing patient survival.
For the pharmaceutical industry, refined diagnostic criteria like A-TANGO are critical. Clinical trials for new ACLF therapies will undoubtedly adopt these updated scores, allowing for more homogeneous patient populations and, theoretically, clearer signals of efficacy. Companies developing drugs for liver failure will need to demonstrate their agents' impact within the framework of these new definitions. This could accelerate drug development by reducing noise in trial outcomes, but it also places a burden on developers to ensure their trial designs align with the most current diagnostic standards.
Patients stand to benefit from more accurate prognostication, which can inform discussions about treatment intensity, palliative care, and realistic expectations. While the immediate impact of a new scoring system might seem abstract, its downstream effects on personalised medicine for ACLF are substantial. The validation of noninvasive fibrosis algorithms in low-resource settings, though separate, further underscores a global push for accessible, accurate diagnostics. This broader trend suggests a future where liver disease diagnosis is less reliant on invasive procedures and more on sophisticated, validated scoring systems, ultimately improving patient care across diverse healthcare environments.
ART-2026-028
William Lopes is the founder and editor of The Life Science Feed. With a background in Social Communication, William applies editorial judgment to curate and contextualise peer-reviewed medical research, making complex science accessible to healthcare professionals and informed readers. Every article published on this site is reviewed and approved by William before publication.
Cite This Article
Team TLSFE. A-tango score refines aclf diagnosis, prognosis in cirrhosis. The Life Science Feed. Updated May 18, 2026. Accessed May 19, 2026. https://thelifesciencefeed.com/hepatology/liver-cirrhosis/research/a-tango-score-refines-aclf-diagnosis-prognosis-cirrhosis.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Engelmann C, Verma N, Qi T. Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts. J Hepatol 2026.
2. Budau KL, Thimme R, Sturm L. [Acute-on-chronic liver failure]. Dtsch Med Wochenschr 2026.
3. Mettananda C, Ranawaka C, Egodage T. Adoption and validation of the European Association for the Study of the Liver algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease in low-resource South Asian settings. PLoS One 2026.
